Premium
Interaction between epidermal growth factor receptor and interleukin‐6 receptor in NSCLC progression
Author(s) -
Yuquan Bai,
Hexiao Tang,
Laiyi Wan,
Gaofeng Pan,
Xuefeng Zhou,
Ming Xu,
Yanhong Wei,
Li Zhang,
Jinping Zhao
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27448
Subject(s) - epidermal growth factor receptor , lung cancer , cancer research , glycoprotein 130 , mapk/erk pathway , protein kinase b , epidermal growth factor , medicine , cytokine , receptor , signal transduction , biology , interleukin 6 , microbiology and biotechnology
Even though the interaction between epithelial growth factor receptor (EGFR) and interleukin‐6 receptor (IL‐6R) has been found in many tumors, there is a lack of relevant in‐depth study of lung cancer. The following study investigates the interaction of EGFR and IL‐6R in lung cancer. In the current study, EGFR, IL‐6, and glycoprotein 130 (GP130) were highly expressed in non–small cell lung cancer (NSCLC) tissue samples and were associated with clinicopathological features and poor prognosis of patients with NSCLC. Furthermore, the effect of EGF and IL‐6 on biological behavior of lung cancer cells (cell proliferation, invasion, cycle, and apoptosis) and the expression of EGFR, GP130, p‐protein kinase B (p‐AKT), and p‐p44/42 mitogen‐activated protein kinase (p‐p44/42 MAPK) was significantly stronger compared with other treatment groups (all P < 0.05). These results suggest that EGFR and IL‐6R have synergistic effects on NSCLC progression. This could help to solve the problem of EGFR inhibitors in the treatment of lung cancer resistance and improve the efficacy of current treatment for lung cancer through a combination of EGFR and IL‐6R signaling pathways.